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Familial hypercholesterolemia (FH) is one of the most prevalent genetic  
disorders leading to premature atherosclerosis and coronary heart disease.  
The main cause of FH is a mutation in the LDL-receptor gene that leads to loss of  
function of these receptors causing high levels of blood cholesterol. The diagnosis 
of FH is not very easy. Wide screenings are needed to reveal high levels of LDL  
cholesterol among “healthy” population. If the patient has MI or stroke at an early 
age, high levels of LDL cholesterol, and tendon xanthomas, the diagnosis of FH 
becomes much more clear. Genetic testing is a gold standard in the diagnosis of 
FH. There are several factors, influencing the time course of FH. Smoking males 
with low levels of HDL cholesterol have an extremely higher risk of death than 
nonsmoking females with high HDL cholesterol. Management of FH includes low 
cholesterol diet, statin and ezetimibe treatment, PCSK inhibitors, and LDL aphae-
resis. Early and effective treatment influences much the prognosis in FH patients.
Keywords: prevalence of familial hypercholesterolemia (FH), diagnosis of FH,  
the time course of FH, treatment of FH
1. Introduction
Familial hypercholesterolemia (FH) is one of the most frequent inherited 
disorders caused mainly by a mutation of the gene encoding the low density lipo-
protein receptor (LDLR). High concentrations of LDL result in uptake of LDL by 
extracellular matrix, including that of the arterial wall leading to premature athero-
sclerosis and coronary artery disease (CAD). CAD develops early with symptoms 
often manifesting in men in the fourth or fifth decade and women about 10 years 
later. Approximately 5% of all cases of premature myocardial infarction (MI) occur 
in patients with heterozygous FH [1, 2]. Before the development of statin therapy, 
at least 50% of FH male patients experienced MI by the age of 60. In homozygotes, 
symptomatic CAD can occur in childhood, and very few survive past the age of 30.
Brown and Goldstein are indisputably the fathers of FH. In 1972, they attributed 
the disorder to defective HMG-CoA reductase [3]. But, a year later they recognized 
that the main cause of the disease was the mutation in the LDLR gene [4]. The 
extremely rare homozygote with FH has two mutant alleles at the LDLR locus, 
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leaving a person with an absolute or nearly absolute inability to clear LDL from 
circulation [1]. Brown and Goldstein initially described homozygous FH (HoFH) as 
a condition in which an individual inherits a single and same mutation in the LDLR 
from each parent. Now we recognize this condition as “simple HoFH” [5]. Actually, 
this is a very rare event. Far more frequently, HoFH is a result of inheritance of two 
different pathogenic mutations in the same gene that is referred to as a “compound 
heterozygote.” Another type of HoFH is when an individual inherits a mutation 
of one gene (e.g., LDLR) from one of the parents and different gene (e.g., apoB or 
PCSK9) from another. This type of HoFH is a “double heterozygote.” It is important 
to know that the term “heterozygote” is used here to describe homozygote patients.
Heterozygotes with FH possess one normal allele, giving them approximately 
one half of the normal receptor activity. Actually, LDLR also contributes to the 
clearance of VLDL remnants from the plasma, so a deficiency of LDLR may lead to 
some accumulation of remnant lipoproteins as well.
Additionally, mutations of other genes such as apoB, PCSK9, and so on are now 
recognized to also cause FH [6–8].
The prevalence of heterozygous FH (HeFH) is about 1/200 [9] and HoFH—
1/160,000 [10, 11]. Therefore, HeFH is a very frequent disorder, and it is more 
common than type 1 diabetes mellitus. Unfortunately, the diagnosis of FH is often 
unrecognized, leaving such individuals and members of their families undertreated 
and of greater risk of consequences of lifelong LDL-C elevations. Nevertheless, 
the prevalence of FH may differ greatly in different populations. For example, 
in French Canadians, South African Afrikaners, Ashkenazi Jews, or Christian 
Lebanese, which are the so-called founder populations, the prevalence of FH can be 
as high as 1/67 [12, 13]. So, it is important to “know your audience” and be on the 
lookout for such individuals in daily clinical practice.
2. Discussion
The diagnosis of FH is simple and complicated at the same time. First of all 
patients with FH should have a very high LDL (>95% for age/gender matched 
controls) with typically normal TG and HDL. For patients with HoFH, LDL is >500 
mg/dl (13 mmol/l) when untreated and >300 mg/dl (7.7 mmol/l)—on lipid-lower-
ing therapy (LLT) [14–16]. The cut point for HeFH in adult had similarly been >190 
mg/dl (5 mmol/l). Recent genotyping studies showed great difference in LDL levels 
among FH patients. To date, the lowest LDL level in untreated FH patient was 
170 mg/dl (4.4 mmol/l) [9]. Still, there is no question that the higher the LDL-C, 
the more aggressive the vascular disease.
The second thing is that patients should have a family history of premature 
atherosclerotic cardiovascular disease (ASCVD), very high cholesterol, or both. 
Premature ASCVD in a patient is often a clue to FH. In fact, 20% of all myocardial 
infarctions (MI) in people under the age of 45 are a consequence of FH [17, 18].
The third thing is that the expected response to lipid-lowering therapy is often 
blunted in FH patients, and their LDL levels are falling less robustly than would 
normally be anticipated. This occurs because standard medications such as statins 
and ezetimibe are concentrated on LDLR upregulation. As these receptors by defini-
tion defective, their upregulation is less effective at internalizing LDL from plasma.
Physical signs of FH depend greatly on type of the mutation, age, gender, and 
other factors.
This is an example of one of our FH patient, a 26-year-old woman, who had 
tendon xanthomas at the age of 1. She have been examined in different clinics 
(mainly, dermatological), but the diagnosis of FH was suspected only at the age 
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of 10 when concentration of total cholesterol was measured (total cholesterol 
level = 21 mmol/l) (Figure 1).
Unfortunately, LLT (statins, ezetimibe, and LDL-apheresis) has been started in 
this patient only at the age of 19. She represents positive stress-echo test, and coro-
nary angiography reveals 50% stenosis of the right coronary artery. A 50% stenosis 
of both common carotid arteries according to an ultrasound was also revealed. At 
present time, this patient receives 80 mg of atorvastatin, 10 mg of ezetimibe, and 
LDL-apheresis procedures (each 2 weeks). She also takes part in a randomized pla-
cebo-controlled international clinical study on a new PCSK9 inhibitor—Inclisiran.
You can see a pedigree of this patient in Figure 2. It is seen that the index patient 
(marked with red arrow) with very high cholesterol level has two still young 
Figure 1. 
Corneal arcus (both the eyes) and tendon xanthomas (hands, Achilles tendon, elbow, and knee) in a 26-year-
old woman with FH.
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parents without clinical signs of ASCVD, but having high total cholesterol levels 
(9.5–12.2 mmol/l). Parents of proband are divorced, and both of them have new 
families. The father’s daughter from the second marriage who is 11 years of age 
has also high cholesterol level (8.5 mmol/l). It is seen that the grandfather of the 
proband died at the age of 54 of acute myocardial infarction (MI).
This patient has undoubtedly homozygous FH phenotype due to a very high 
cholesterol level, premature atherosclerosis, tendon xanthomas, family history of 
hypercholesterolemia, and premature ASCVD. Nevertheless, it was interesting to 
perform genetic testing in this family.
This test was performed in Health-In-Code genetic laboratory (Spain) using 
Next Generation Sequencing (NGS). Patient specimen (blood) was subjected to 
automated genomic DNA purification (QIAsymphony SP®, Qiagen). Library 
preparation was carried out using the Agilent SureSelect library preparation kit 
for Illumina paired-end multiplexed sequencing according to the manufacturer’s 
instructions. Enrichment of regions of interest was performed using a SureSelect 
probe kit (Agilent) that selectively captures the coding regions and adjacent 
intronic areas of the selected genes. After cluster generation, captured DNA was 
sequenced on the Illumina HiSeq 1500 platform. Sequencing data analysis was done 
using a proprietary bioinformatics pipeline that includes sample demultiplexing as 
well as all the steps necessary to obtain a report of annotated variants together with 
their coverage and corresponding quality parameters.
The design of the custom capture library includes the following six genes 
related to familial hypercholesterolemia: APOB, APOE, LDLR, LDLRAP1, PCSK9, 
and SLCO1B1.
The genes included in this test have been selected on a clinical basis according 
to their relation to a particular phenotype and classified on the basis of evidence 
supporting this association into priority, secondary, and candidate genes.
Probes were designed to adequately cover all coding exons and 10 base pairs 
(bp) of flanking intronic sequences; therefore, this test is unable to identify genetic 
variants located in intronic zones far from splice sites or UTR regions.
Analysis of SNVs and INDELs: This test can identify single-nucleotide variants 
(SNVs) and insertions/deletions (INDELs) of up to 20 bp. Genetic variants are 
reported following the Human Genome Variation Society (HGVS) recommendations 
(www.hgvs.org).
Genetic variants that are selected because of their potential association with the 
patient’s phenotype or constitute relevant incidental findings are reported in the 
main table of the report on the first page. Please note that a variant’s pathogenicity 
may be subject to change as new scientific evidence appears.
Figure 2. 
Pedigree of a 26-year-old female (23 at entry).
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Confirmation studies: Variants included in the main table meeting the condi-
tions below are confirmed by orthogonal testing:
• point variants (SNVs) and insertions, deletions, and/or INDELs of ≤4 bp that 
meet at least one of the following criteria: called by only one variant caller, 
suboptimal quality (QUAL <100), depth of coverage <30x, variants in low-
mappability, or multiple alignment regions and
• insertions, deletions, and/or INDELs of >4 bp.
Similarly, low-coverage regions in priority genes that may be of clinical interest 
are resequenced by the Sanger method.
Analysis of CNVs: Health-In-Code has developed an alternative bioinformat-
ics pipeline that is also able to identify gross insertions/deletions affecting one or 
more exons of a gene/s included in the panel (CNVs: copy number variations). This 
complementary analysis is possible when bioinformatics data are adequate (evalu-
able CNVs) and may not be available in all studies (nonevaluable CNVs).
CNV confirmation studies: Variants identified using this technique will be 
confirmed by an adequate alternative method.
Analytical specifications of the test: Both analytical sensitivity and specificity 
of this test are greater than 99% for single-nucleotide variants (SNVs) and inser-
tions/deletions (INDELs) of ≤20 bp.
Average coverage values of the tested gene/s and other quality parameters 
specific to this patient’s study are detailed in each study report.
Technical limitations that can be in any study report: Despite the high sensitivity 
and specificity of this test, some genotyping errors may occur in specific situations:
• contamination of samples before they arrive at our laboratory;
• mosaic variants;
• monosomies and trisomies;
• genetic paternity problems;
• genetic variants producing allelic drop-outs;
• studies performed on paraffin-embedded tissues;
• presence of pseudogenes (homologous regions);
• incorrect identification of variants in homopolymer or high GC-content zones; 
and
• errors in the reference sequence
This study is usually not able to identify the phase (same/different alleles) of 
more than one variant affecting the same gene. This limitation should be considered 
in cases of recessive disorders, which occur only when both alleles are mutated.
Unequivocal traceability: Health-In-Code developed in-house software 
NextLIMS that efficiently identifies and tracks samples in the laboratory and allows 
to unequivocally trace the steps a sample has already gone through.
As you can see in Figure 3, two different mutations in the LDLR gene were 
revealed. First mutation (Val806Glyfs*11) has been previously described and was 
also found in the mother of proband. Second mutation (Asp569Val) was a new one 
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(never described in the literature previously). The same mutation was found in a 
father’s daughter from the second marriage. Therefore, in case that each variant 
affects a different copy of the gene (we call this condition as compound heterozy-
gote), the expected phenotype is homozygous familial hypercholesterolemia.
This clinical case shows difficulties in the diagnosis of FH despite of the pres-
ence of obvious facts that actually led to the late onset of LLT and marked athero-
sclerotic lesions of coronary and carotid arteries in a young patient.
Another patient is a female, 42 years of age with high total cholesterol level 
(11–12 mmol/l) known for 10 years with no signs of ASCVD. Stress test is negative, 
intima-media thickness of carotid arteries is 0.8 mm, and no tendon xanthomas or 
corneal arcus.
It is seen that the father of the proband died at the age of 56 of MI, her aunt at 
the age of 69 has high cholesterol and angina pectoris, and her cousin at the age of 
45 has high cholesterol and underwent CABG (Figures 4 and 5).
This clinical case is an example of mutation of apoB gene that also leads to 
hypercholesterolemia. Familial ligand defective apolipoprotein B (FDB) was first 
described in 1986 by Vega and Grundy [19]. In lipoprotein kinetic studies, it was 
observed that LDL from some donors was cleared more slowly from circulation in 
individuals with normal LDL receptor function. Genomic DNA analysis revealed a 
point mutation in Apo B: CGG-to-CAG mutation at the codon for amino acid 3500 
resulting in an arginine to glutamine substitution. The prevalence of this disorder 
is unknown but is estimated to be 5–10% that seen in FH. Hypercholesterolemia 
in FDB is usually less severe than in FH. Patients with FDB do respond to statin 
drug therapy, probably reflecting increased removal of Apo E-containing remnant 
particles through upregulated hepatic LDL receptors. Our patient was treated with 
rosuvastatin 40 mg/day + ezetimibe 10 mg/day. Her total cholesterol is 4.9 mmol/l; 
LDL cholesterol is 2.3 mmol/l; HDL cholesterol is 1.8 mmol/l; and TG is 1.6 mmol/l.
Figure 3. 
Results of genetic testing in a 26-year-old female, performed in Health-In-Code genetic laboratory (Spain).
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Physical signs of FH can occur but not needed for the diagnosis. Extensor tendon 
xanthomas, typically affecting the Achilles or the hands, could appear at the age of 20 
and may be present in 70% of older patients. Because xanthomas are subtle, careful 
examination of the dorsal hand tendons and Achilles tendon is required for their 
detection. Thus, it is important to always examine the Achilles tendon when perform-
ing physical exam. Xanthelasma (cutaneous xanthomas on the palpebra) is common 
in patients with FH after the age of 30; however, it is not specific for FH. With regard 
to corneal arcus, it does not have to be circumferential. In fact, it often starts in the 
superior and inferior aspects of the cornea where the blood supply is greatest. Also, 
a corneal arcus in someone under 45 years of age is pathognomic for FH [20]. It is 
important to recognize that because of the prevalent use of lipid-lowering therapy 
xanthomas, and other clinical signs of FH are uncommon findings nowadays.
Figure 5. 
Results of genetic testing in a 42-year-old woman with high cholesterol level.
Figure 4. 
Pedigree of a 42-year-old woman with high cholesterol level.
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Although most FH specialists diagnose FH on clinical grounds, three systems are 
also available: Make Early Diagnosis to Prevent Early Death (MEDPED), the Dutch 
Lipid Clinic Network (DLCN), and Simon Broom. Each has its own pros and cons, 
and none is essential to make the diagnosis. Nevertheless, it is useful to utilize them 
in clinical practice.
As it is clear from Table 1, if a patient has LDL-C level ≥8.5 mmol/l and prema-
ture coronary artery or cerebral artery disease, he/she already has more than eight 
points that means definite FH. It is important to know that if a person has positive 
results of genetic testing, he/she has only eight points and it is not enough to make a 
diagnose of definite FH.
Once the diagnosis of FH has been made, he/she is dubbed the proband or the 
index case. As FH is an autosomal dominant disorder, and early diagnosis and 
treatment dramatically reduce the risk of future ASCVD events, it is important 
for physicians to identify other members of the family. Screening relatives of the 
proband is called “cascade screening.”
There are two methods of cascade screening, active and passive. Passive screen-
ing employs the index case as the messenger to inform the other family members 
and recommend further testing. Passive screening is usually not very successful. 
In contradistinction, active cascade screening—a system in which clinicians rather 
than patients seek out affected family members—is extraordinarily effective.  
*Premature = <55 years in men; <60 years in women.
LDL-C, low-density lipoprotein cholesterol; LDLR, low-density lipoprotein receptor; apoB, apolipoprotein B; 
PCSK9, proprotein convertase subtilisin/kexin type 9.
Table 1. 
Dutch Lipid Clinic Network Score for FH [21–23].
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It was successfully performed in the Netherlands. This active cascade screening system 
sets the bar for the world, identifying nearly 75% of the Netherland’s FH population 
and adding eight additional FH patients for every single-index case identified [9].
The time course of FH depends on a lot of genetic and environmental factors. 
Previously, we have identified mutations of the LDLR gene in 45 families in St. 
Petersburg [24]. Our aim was to follow the development of dyslipidemia in children 
of probands with verified mutations of the LDLR gene as these children were grow-
ing up, to compare severity of atherosclerotic complications in patients with differ-
ent LDLR gene mutations, and to compare atherosclerotic disease progress in males 
and females with FH. We were following probands with FH and their available rela-
tives with LDLR gene mutations, including children, during 10 years. In all patients, 
total blood plasma cholesterol, triglycerides, LDL cholesterol, and HDL cholesterol 
were monitored, and clinical manifestations of ASCVD were documented.
As it is seen in Table 2, there were 26 original mutations of the LDLR gene, and 
7 were not original but revealed in different families. Due to high heterogeneity of 
FH-causing mutation in St. Petersburg, we failed to establish interrelations between 
type of LDLR gene mutation and severity of atherosclerosis manifestation. As a 
rule, complications of coronary artery disease (CAD) were found less commonly 
and tend to be less severe in females rather than in males (Table 3).
As you can see in Table 3, CAD was revealed in three-fourth of males with LDLR 
gene mutations and only in half of females. Thus, mean age of healthy persons was 
34 ± 3.1 years in males and 41 ± 2.6 years in females. Mean age of patients with CAD 
clinical manifestations was 45 ± 1.9 and 53 ± 2.9, respectively. Otherwise, males suffer 
from atherosclerotic complications more frequently and much earlier than females. 
Apparently, females are defended of ASCVD anyway in cases of FH. Some authors 
explain this by protective function of estrogens. Not infrequently, this protection 
still remains in the menopause period. To our mind, this protective effect could be 
explained by the level of HDL cholesterol. Thus, we followed up a mother and her 
two daughters with genetically verified diagnosis of FH. Mother and her younger 
daughter had severe clinical manifestations of CAD, while older daughter had no 







members of families 
of probands 







Number of families 
with the same 
type of LDLR gene 




the same (only 
one) mutation 
(G197del)
45 78 26 6 (12 probands, 
6 variants of 
the LDLR gene 
mutation)
7 probands with 
1 variant of 
mutation
Table 2. 











Mean age of 
patients without 
CAD
Male 26 20 45 ± 1.9 6 34 ± 3.1
Female 38 19 53 ± 2.9 19 41 ± 2.6
Table 3. 
Number of males and females with the LDLR gene mutations, their age, and the presence of coronary heart 
disease.
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greatly in the members of this family (326 mg/dl—mother, 322 mg/dl—younger 
daughter (24-year-old), 277 mg/dl—older daughter (30-year-old)), while HDL-C 
was 44 mg/dl and 49 mg/dl in the first two woman and 65 mg/dl—in the third.
We divided patients with LDLR gene mutations into three groups (Table 4). 
1 with progressive CAD, 2 with stable disease, 3 without clinical manifestation of 
CAD and measured LDL/HDL ratio.
It is seen that high level of HDL is the only one proved lipid factor prevent-
ing atherosclerosis development in patients with genetically verified familial 
hypercholesterolemia.
3. Conclusion
Management of FH must always begin with therapeutic lifestyle changes (TLC); 
therefore, TLC is the foundation of all ASCVD prevention [25]. A healthful diet 
limited in saturated fats and simple sugars, daily aerobic exercise, avoidance of 
tobacco and alcohol, maintenance of an optimal blood pressure and weight, and 
reduction of stress are all important. The mainstay of therapy in FH is to lower the 
LDL-C as much and as soon as possible. One must remember that all patients with 
FH are considered high cardiovascular risk, and for this reason, formal risk strati-
fication with Framingham or Score systems is never advised when guiding treat-
ment. According to the European Guidelines, the goal of lipid-lowering therapy is 
<1.4 mmol/l if the patient has CAD, diabetes mellitus or >50% stenosis of carotid 
or peripheral arteries, and <1.8 mmol/l—without clinical manifestations of ASCVD 
[26]. It is recommended in adult patients to use high intensive statin therapy 
(atorvastatin 80 mg or rosuvastatin 40 mg). In cases where the goal is not achieved 
on statin therapy, it is recommended to add ezetimibe 10 mg. If the goal is not 
achieved, you should think about adding PCSK9 inhibitors (alirocumab 75/150 mg 
each 2 weeks, evolocumab 140 mg each 2 weeks or 420 mg once a month).
Drug therapy in children with FH should be started at the age of 8–10 years. 
The LDL-C goal is <4.0 mmol/l (8–10 years) and <3.5 mmol/l (10 years and more). 
Treatment should be started with statins. In case of homozygous FH when LDL-C 
levels are more than 13 mmol/l and ASCVD appears in childhood, the treatment 
should be started from a maximal doses of statins with the addition of ezetimibe 
and evolocumab (in children >12 years). In severe cases of HoFH, extracorporeal 
methods of treatment (LDL apheresis, HELP, etc.) are recommended.
Despite of the fact that pathogenesis and clinical manifestations of FH are well 
understood, this disease still remains underdiagnosed and undertreated. All FH 
patients are to be considered high risk. Some, however, are unfortunately even 
higher risk than rest. It depends on age, gender, or some biochemical and envi-
ronmental risk and antirisk factors. Early diagnosis and management of FH can 
significantly improve lifespan and quality of life in these patients.





Group 1 15 10.4 ± 0.78
Group 2 8 7.7 ± 0.89 
Group 3 10 5.2 ± 0.45
Difference between Groups 1 and 2 and Groups 2 and 3 is statistically significant (p<0.05).
Table 4. 
LDL/HDL ratio in the three groups of patients with LDLR gene mutations.
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